[go: up one dir, main page]

MX2009006972A - Derivados de espiropiperidina como antagonistas de neuroquinina 3. - Google Patents

Derivados de espiropiperidina como antagonistas de neuroquinina 3.

Info

Publication number
MX2009006972A
MX2009006972A MX2009006972A MX2009006972A MX2009006972A MX 2009006972 A MX2009006972 A MX 2009006972A MX 2009006972 A MX2009006972 A MX 2009006972A MX 2009006972 A MX2009006972 A MX 2009006972A MX 2009006972 A MX2009006972 A MX 2009006972A
Authority
MX
Mexico
Prior art keywords
lower alkyl
halogen
hydrogen
optionally substituted
heteroaryl
Prior art date
Application number
MX2009006972A
Other languages
English (en)
Inventor
Michael Patrick Dillon
Hasane Ratni
Bo Han
Matthias Nettekoven
Walter Vifian
Joanie Marie Caroon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009006972A publication Critical patent/MX2009006972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I), en donde R1 es hidrógeno o alquilo inferior; R2 es alquilo inferior, hidroxialquilo inferior o -(CHR5)x-A; R5 es hidrógeno, alquilo inferior o hidroxialquilo inferior, o es heteroarilo opcionalmente sustituido por alquilo inferior; A es cicloalquilo, arilo, heterociclilo o heteroarilo, en el cual los anillos son opcionalmente sustituidos por uno o más R6, en donde R6 es alquilo inferior, alcoxi inferior, alquilsulfonilo inferior, ciano, halógeno, alquilo inferior sustituido por halógeno o alcoxi inferior sustituido por halógeno, o es arilo, heterociclilo o heteroarilo opcionalmente sustituido por alquilo inferior o es cicloalquilo opcionalmente sustituido por alquilo inferior; x es 0, 1, 2 o 3; o R1, R2 puede formar junto con el heterociclilo o heteroarilo del átomo de N, en el cual los anillos son opcionalmente sustituidos por uno o más sustituyentes seleccionados a partir del grupo que consiste de alquilo inferior, alcoxi inferior, alquilsulfonilo inferior, halógeno, cicloalquilo, bencilo o arilo; R3 es hidrógeno o halógeno; R4 es hidrógeno o alquilo inferior; R7 es hidrógeno, halógeno o alquilo inferior; m es 1 o 2; cuando m es 2, R3 puede ser el mismo o no; n es 1 o 2; o es 1 o 2; cuando o es 2, R7 puede ser el mismo o no; o a una sal de adición del mismo de ácido farmacéuticamente adecuado. Se ha encontrado que los presentes compuestos son antagonistas del receptor NK-3 de alto potencial, para el tratamiento de depresión, dolor, psicosis, enfermedad de Parkinson, esquizofrenia, ansiedad y trastornos de hiperactividad de déficit de atención (ADHD).
MX2009006972A 2007-01-03 2008-01-02 Derivados de espiropiperidina como antagonistas de neuroquinina 3. MX2009006972A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100064 2007-01-03
PCT/EP2008/050005 WO2008081012A1 (en) 2007-01-03 2008-01-02 Spiropiperidine derivatives as nk3 antagonists

Publications (1)

Publication Number Publication Date
MX2009006972A true MX2009006972A (es) 2009-07-09

Family

ID=39387329

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006972A MX2009006972A (es) 2007-01-03 2008-01-02 Derivados de espiropiperidina como antagonistas de neuroquinina 3.

Country Status (12)

Country Link
US (1) US7470684B2 (es)
EP (1) EP2099806B1 (es)
JP (1) JP5073758B2 (es)
KR (1) KR101189031B1 (es)
CN (1) CN101622259B (es)
AT (1) ATE546455T1 (es)
AU (1) AU2008203707B2 (es)
BR (1) BRPI0806483A2 (es)
CA (1) CA2674141A1 (es)
ES (1) ES2380270T3 (es)
MX (1) MX2009006972A (es)
WO (1) WO2008081012A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101372743B1 (ko) * 2009-01-30 2014-03-14 에프. 호프만-라 로슈 아게 Ｎｋ3 수용체 길항제로서 피페리딘 유도체
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029027A1 (en) * 1999-10-22 2001-04-26 Sankyo Company, Limited 2-alkoxybenzene derivatives
BR0209604A (pt) * 2001-05-14 2004-03-23 Hoffmann La Roche Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas e seu uso como antagonista do receptor para neuricinina
JP2007530656A (ja) 2004-03-29 2007-11-01 ファイザー株式会社 ＯＲＬ１受容体拮抗薬としてのαアリールまたはヘテロアリールメチルβピペリジノプロパンアミド化合物

Also Published As

Publication number Publication date
US7470684B2 (en) 2008-12-30
AU2008203707A1 (en) 2008-07-10
US20080176839A1 (en) 2008-07-24
KR101189031B1 (ko) 2012-10-08
ES2380270T3 (es) 2012-05-10
BRPI0806483A2 (pt) 2011-09-27
EP2099806A1 (en) 2009-09-16
CN101622259A (zh) 2010-01-06
AU2008203707B2 (en) 2012-06-21
ATE546455T1 (de) 2012-03-15
JP2010514816A (ja) 2010-05-06
EP2099806B1 (en) 2012-02-22
KR20090096645A (ko) 2009-09-11
CA2674141A1 (en) 2008-07-10
CN101622259B (zh) 2012-02-01
JP5073758B2 (ja) 2012-11-14
WO2008081012A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
CY1116778T1 (el) Παραγωγα πυραζολιου
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
PE20130155A1 (es) Derivados de ariletinilo
PE20130647A1 (es) Indoles
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
TW200732329A (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
MY163164A (en) Ethynyl derivatives as positive allosteric modulators of the mglur5
MX2009009384A (es) Malonamidas como antagonistas de orexina.
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PH12016501100B1 (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
MX2011008850A (es) Derivados de piperidina como antagonistas del receptor de neuroquinina 3 (nk3).
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
MX2012008147A (es) Derivados de pirrazolopiridina.
PE20141168A1 (es) Derivados de pirazolidin-3-ona
MX2009010727A (es) Heterociclos como antagonistas de orexina.
MX2009006972A (es) Derivados de espiropiperidina como antagonistas de neuroquinina 3.
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
MX2013007411A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).
BR112012014576A2 (pt) derivados de pirrolidina como antagonistas do receptor nk-3
MX2011008178A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinina 3 (nk3).

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration